Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Stevanato Group S.p.A. is a global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. The company operates at the intersection of pharmaceutical manufacturing and advanced engineering, supplying critical components that enable safe storage, administration, and analysis of injectable drugs and diagnostic samples. Its core offering supports biologics, vaccines, and other complex injectable therapies, positioning the company as a key infrastructure partner within the global healthcare supply chain.
Founded in 1949 in Italy as a glass manufacturing business, Stevanato Group evolved over decades from a local producer of glass containers into an integrated international solutions provider. Through sustained investment in engineering, automation, and pharmaceutical-grade manufacturing standards, the company expanded its capabilities beyond primary packaging into drug delivery systems, inspection technologies, and end-to-end solutions tailored to regulated pharmaceutical environments.
Business Operations
Stevanato Group generates revenue primarily through two operating segments: Biopharmaceutical and Diagnostic Solutions and Engineering. The Biopharmaceutical and Diagnostic Solutions segment includes high-quality glass primary containers such as vials, syringes, and cartridges, as well as integrated drug delivery systems and diagnostic consumables. These products are manufactured using proprietary processes and are designed to meet stringent regulatory and performance requirements of pharmaceutical and diagnostic customers.
The Engineering segment designs and supplies industrial equipment, including glass forming, inspection, and assembly systems used in pharmaceutical manufacturing. This segment also provides after-sales services and supports both internal production and external customers. The company operates manufacturing and engineering facilities across multiple countries and serves a diversified global customer base that includes large pharmaceutical companies, biotechnology firms, and diagnostic solution providers.
Strategic Position & Investments
Stevanato Group’s strategy focuses on long-term growth driven by increasing demand for injectable biologics, vaccines, and advanced therapeutics. The company continues to invest in capacity expansion, automation, and proprietary technologies that enhance product quality, scalability, and regulatory compliance. A key strategic priority is the integration of primary packaging with drug delivery and inspection solutions, enabling customers to streamline development and manufacturing processes.
The company has made targeted investments to expand its high-value product portfolio, including ready-to-use containers, advanced polymer-based delivery systems, and integrated solutions for biologics. Stevanato Group also invests in emerging technologies related to combination products and digital inspection systems, reinforcing its position as a solutions-oriented partner rather than a commodity packaging supplier.
Geographic Footprint
Stevanato Group is headquartered in Italy and operates a global manufacturing and commercial network spanning Europe, North America, South America, and Asia. The company maintains significant production and engineering operations in Italy, the United States, Germany, Denmark, Mexico, Brazil, and China, among other locations, supporting proximity to major pharmaceutical hubs.
Its geographic diversification allows the company to serve multinational pharmaceutical customers across key healthcare markets while mitigating supply chain risk. Stevanato Group’s international footprint also supports regulatory alignment with regional standards, including U.S. FDA and European Medicines Agency requirements, enhancing its competitiveness in highly regulated markets.
Leadership & Governance
Stevanato Group is a family-founded company that remains influenced by its entrepreneurial heritage while operating under a modern corporate governance framework as a publicly listed entity. The leadership team emphasizes long-term value creation, operational excellence, and sustained investment in technology and people to support customers’ evolving needs in the pharmaceutical and life sciences sectors.
Key executives include:
- Franco Stevanato – Executive Chairman
- Marco Dal Bo – Chief Executive Officer
- Franco Moro – Chief Financial Officer
- Davide Brambilla – Chief Business Officer, Biopharmaceutical and Diagnostic Solutions
- Marco Trabucco – Chief Business Officer, Engineering
The leadership’s strategic vision centers on innovation-driven growth, disciplined capital allocation, and maintaining high quality and compliance standards across global operations.